Zobrazeno 1 - 10 of 53 pro vyhledávání: '"Acr20 response"'
1
Is obesity a predictor for lack of response to treatment in psoriatic arthritis? A systematic review
Autor: Teresa Otón, Jordi Gratacós, Eva Galindez
Publikováno v: Reumatología Clínica (English Edition). 17:268-278
Objectives To update the study of the association between obesity and treatment response in psoriatic arthritis. Methods Updating a systematic review of clinical trials, prospective or retrospective longitudinal studies and case–control studies in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c48d7499a52149525ec695852d28f51
https://doi.org/10.1016/j.reumae.2019.06.003
Zobrazit plný text záznamu
2
Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
Autor: T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Eremeeva, M. A. Morozova
Publikováno v: Научно-практическая ревматология, Vol 58, Iss 5, Pp 480-488 (2020)
Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Here, we present the results of the 24-weeks double blind perio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6078653573989481551d13e5e15654
https://doi.org/10.47360/1995-4484-2020-480-488
Zobrazit plný text záznamu
3
Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
Autor: E. L. Nasonov, M. L. Stanislav, T. A. Raskina, G. V. Kuropatkin, I. V. Shirinsky, A. P. Rebrov, N. A. Shostak, B. A. Alikhanov, E. N. Ushakov, R. G. Kamalova, S. A. Smakotina, V. I. Simanenkov, A. S. Pavsun, I. I. Zaharjan, S. S. Yakushin, M. Yu. Sandin
Publikováno v: Научно-практическая ревматология, Vol 57, Iss 2, Pp 142-148 (2019)
Objective: to study the efficacy and safety of rheumatoid arthritis (RA) treatment with monoclonal antibodies to interleukin 6 receptors (IL6R) – sarilumab (SAR) in combination with methotrexate (MT).Subjects and methods. The study included adult p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::317d701192a3e451a5e7b4a24e34b98a
https://doi.org/10.14412/1995-4484-2019-142-148
Zobrazit plný text záznamu
4
OP0227 EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Autor: Alan Kivitz, D. van der Heijde, Marleen Nys, Frank Behrens, A. Deodhar, S. Banerjee, T. Lehman, Miroslawa Nowak, P. J. Mease, L. Wei
Publikováno v: Annals of the Rheumatic Diseases. 80:137-138
Background:Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates IL-23, IL-12, and IFNα/β signaling. Deucravacitinib is a novel, oral selective inhibitor of TYK2 acting via the TYK2 regulatory domain. Phase 2 results showed deucravaciti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9fb4115f4c230f57d55e87711d89044
https://doi.org/10.1136/annrheumdis-2021-eular.2653
Zobrazit plný text záznamu
6
OP0230 EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
Autor: May Shawi, Laure Gossec, M. Neuhold, Laura C. Coates, Georg Schett, E. Theander, Chetan S Karyekar, I.B. McInnes, W. Noel, P. Bergmans
Publikováno v: Annals of the Rheumatic Diseases. 80:140-141
Background:Guselkumab (GUS), a selective monoclonal antibody targeting the interleukin-23p19 subunit, has demonstrated efficacy in 2 pivotal Ph3 psoriatic arthritis (PsA) studies (DISCOVER-1,1 DISCOVER-22).Objectives:Evaluate GUS efficacy and safety
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0bbe464a6c179ea9faa6f49852c1fc89
https://doi.org/10.1136/annrheumdis-2021-eular.42
Zobrazit plný text záznamu
7
AB0525 GUSELKUMAB TREATMENT SHOWS RAPID ONSET OF EFFECT ON COMPONENTS OF AMERICAN COLLEGE OF RHEUMATOLOGY RESPONSE CRITERIA: RESULTS OF 2 RANDOMIZED PHASE 3 TRIALS
Autor: A. Deodhar, Peter Nash, May Shawi, S. Sheng, Ying Ying Leung, Stephen Xu, D. Furtner, Christopher T. Ritchlin, Iain B. McInnes, W. C. Tsai, Lai-Shan Tam, A. Kollmeier
Publikováno v: Annals of the Rheumatic Diseases. 80:1290-1291
Background:Guselkumab (GUS), an anti-interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy vs placebo (PBO) in achieving American College of Rheumatology 20% improvement (ACR20) response in patients (pts) with active psoriatic arthriti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d5c96d90fe476e03d6188c6a5daf92b
https://doi.org/10.1136/annrheumdis-2021-eular.434
Zobrazit plný text záznamu
9
OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
Autor: A. Kavanaugh, Shephard Mpofu, Ruvie Martin, Tatiana Korotaeva, I.B. McInnes, P. Nash, Alice B. Gottlieb, J. Gratacos-Masmitja, Luminita Pricop, P. J. Mease, Pascale Pellet, F. Behrens, Philippe Goupille, Christopher T. Ritchlin, Kevin Ding
Publikováno v: Annals of the Rheumatic Diseases. 79:142-143
Background:Secukinumab (SEC), an interleukin-17A inhibitor, has demonstrated improvements on multiple domains of psoriatic arthritis (PsA).1Adalimumab (ADA), a TNF inhibitor, is widely used as a first–line biologic in PsA.Objectives:To report effic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66fcc967b8eab9c850f91379544e6c88
https://doi.org/10.1136/annrheumdis-2020-eular.4129
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje